That patient advocate/physician that was quoted after LP in the updated version, is looking at the cost and current means of production. We all know, as Dr. Ashkan stated in 2018, that cost needs to be brought right down. That is the objective of Flaskwork’s invention. It does not need high cost clean rooms and the production per worker is multiplied. Both of these lower costs. Also, the number of batches produced per square foot will go up exponentially. Again saving costs.
I can’t blame the physician for pointing out the costs of the specials program batches, because she has to deal with patients immediately. She needs to see patient access for everyone now!
By lowering cost, Flaskworks will also make the potential for SOC status much more likely, because the NHS bases it’s decisions on cost as well as efficacy.
In The Meantime
There are government reimbursement options that could and should be accessed through the MHRA prior to potential NICE assessment for treatments that are otherwise unlikely to get NICE appraisal within three months or more after marketing approval. This program just started last year, and it feels like it was tailored for therapies like DCVax-l.
Make no mistake about it, there are ways the UK can reimburse prior to NICE’s ability to appraise. The Dr. above is really making the case, whether she intended to or not, to allow such reimbursement if and when marketing approval occurs. (Perhaps even before, as there is another reimbursement program for not yet approved medicinals in some cases)
The case must be made to reimburse as soon as possible (if results are good), and to do that, they must show unmet need.
News 
Market Data 
Discover 
